Concepedia

Antonio Avallone

AA

Statistics

Publications

133

Citations

7.3K

H-Index

42

Active since

1987

Affiliations

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"(Current)

University of Campania "Luigi Vanvitelli"

Istituti di Ricovero e Cura a Carattere Scientifico

University of Naples Federico II

Fondazione IRCCS Istituto Nazionale dei Tumori

Antonio Avallone is an author at Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" specializing in medicine, oncology, and radiation oncology.

ORCID

Top concepts

Publications per year

1987–2025

133

Publications

133

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Giulia Siravegna, Benedetta Mussolin, Michela Buscarino et al. · Nature Medicine · 2015 · 1.1K citations · Full text

, , +6

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

Do‐Youn Oh, Aiwu Ruth He, Shukui Qin et al. · NEJM Evidence · 2022 · 986 citations

, , +15

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 254 citations · Full text

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.

Do‐Youn Oh, Aiwu Ruth He, Shukui Qin et al. · Journal of Clinical Oncology · 2022 · 230 citations

, , +18

18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer.

Giuseppe Lucio Cascini, Antonio Avallone, Paolo Delrio et al. · PubMed · 2006 · 216 citations

1–5 of 133